Related Experiment Video
Updated: Jan 13, 2026
Design and Development of Aptamer–Gold Nanoparticle Based Colorimetric Assays for In-the-field Applications
Published on: June 23, 2016
Metal-Organic Framework@Gold Nanoparticles Enables Point-of-Care Diagnostics To Have Comparable Analytical
Fengli Chai1,2, Dou Wang2, Fenggang Li1,2
1School of Mechatronical Engineering, School of Life Science, and State Key Laboratory of Chips and Systems for Advanced Light Field Display, School of Integrated Circuits and Electronics, Beijing Institute of Technology, Beijing 100081, P. R. China.
Abstract:
Lateral flow immunoassay (LFIA) is a vital point-of-care testing (POCT) technique that is widely used for on-site detection and in vitro diagnosis. Many diseases, particularly cardiovascular diseases (CVDs), require the quantitative detection of multiple biomarkers across a broad dynamic range. Recurrent viral infections like COVID-19 elevate CVDs risk, necessitating early warning and prognostic monitoring, especially based on POCT of multiple blood biomarkers of D-dimer, NT-proBNP, and cTnI across a broad range from pg/mL to μg/mL. Traditional LFIAs lack ultrasensitivity and broad-range quantification. We design the surface chemistry-mediated template-free assembly of metal-aggregation-induced emission luminogens (AIEgen) framework@gold nanoparticles (MAF@AuNPs) for developing ultrasensitive and dynamic dual-quantitative LFIA (ddLFIA). The template-free self-assembled MAF@AuNPs have strong fluorescent and plasmonic properties, avoiding complicated synthesis, chemical modifications, and covalent conjugations, thus leading to highly convenient and versatile visual POCT. MAF@AuNPs ddLFIA achieves a normal detection at ng/mL using chromogenic AuNPs and ultrasensitive detection at pg/mL using fluorogenic MAFs, for which the fluorescence signal is 102-103 times more sensitive than the color signal. MAFs and AuNPs are functionally complementary to form a dynamic, broad-range quantification system covering over 5 orders of magnitude, at the same time having a naked eye sensitivity near 1 pg/mL. The visual POCT using MAF@AuNPs ddLFIA aligns well with clinical chemiluminescent assays. MAF@AuNPs ddLFIA perfectly matches ultrasensitive and broad-range multiple biomarker detections for clinical CVDs diagnosis.
